Skip to main content
. Author manuscript; available in PMC: 2022 Nov 2.
Published in final edited form as: Pediatr Nephrol. 2022 Jan 26;37(9):2141–2150. doi: 10.1007/s00467-022-05445-0

Fig. 1.

Fig. 1

Change in serum creatinine (A and B) and standardized creatinine (SCr/Q; C and D) in participants designated male at birth (DMAB) treated with estradiol (A and C) and in participants designated female at birth (DFAB) treated with testosterone (B and D) during gender-affirming hormone treatment. SCr/Q was calculated using the Q equations corresponding to the participants’ sex designated at birth (closed squares and solid line) and corresponding to the participants’ gender identity (open squares and dashed lines). Symbols indicate means, and lines represent standard deviations. An asterisk indicates a significant change from the previous timepoint (p < 0.05). Creatinine decreased significantly in participants DMAB and increased significantly in participants DFAB from baseline to 6 months (p < 0.001 for both). Serum creatinine continued to increase from 6 to 12 months in participants DFAB (p < 0.001). Standardized creatinine increased from 0 to 6 months in both participants DMAB and DFAB using either equation (p < 0.001 for all comparisons) and did not increase further